Kineta and TuHURA Biosciences Announce Merger Agreement

New activity is brewing for Kineta ( (KANT) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.

On December 11, 2024, Kineta, Inc. and TuHURA Biosciences, Inc. entered into a merger agreement, which was amended on May 5, 2025. The merger involves TuHURA acquiring Kineta in a cash and stock transaction, with Kineta surviving the merger. Special meetings for stockholders of both companies are scheduled for June 23, 2025, to vote on the merger and related proposals. The merger will result in Kineta stockholders holding approximately 7% of TuHURA’s shares post-merger. Additionally, Kineta has agreed to sell certain assets, including its partnered programs and KCP506 product candidate, to other companies. These transactions are part of the strategic realignment ahead of the merger, impacting the company’s operations and market positioning.

Spark’s Take on KANT Stock

According to Spark, TipRanks’ AI Analyst, KANT is a Neutral.

Kineta faces financial challenges and lacks profitability, reflected in a low financial performance score. Technical analysis shows no strong trends, and valuation metrics are unappealing due to negative earnings. The recent merger announcement offers a positive outlook, but overall risks weigh heavily.

To see Spark’s full report on KANT stock, click here.

More about Kineta

Kineta, Inc. is a Delaware-based corporation involved in the biopharmaceutical industry. The company focuses on developing innovative therapies, particularly in the area of chronic pain treatment, with products like KCP506. Kineta has also been involved in various partnerships with major pharmaceutical companies such as Merck, Genentech, and FAIR Therapeutics.

Average Trading Volume: 13,228

Technical Sentiment Signal: Sell

Current Market Cap: $3.39M

Find detailed analytics on KANT stock on TipRanks’ Stock Analysis page.